일즈병의 치료에서 레이저광응고술과 유리체강내 베바시주맙 주입 병합 치료의 효과

• 영문명: Combined Therapy of Laser Photocoagulation and Bevacizumab in Eales’ Disease
• 발행기관: 대한검안학회
• 저자명: 윤창기(Chang Ki Yoon) 이동은(Dong Eun Lee) 김현웅(Hyun Woong Kim)
• 간행물 정보: 『Annals of optometry and contact lens』Vol.15 No.1, 14~20쪽, 전체 7쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2016.03.30

영문 초록

Purpose: To evaluate clinical outcomes of a combined therapy of laser photocoagulation and intravitreal bevacizumab for vitreous hemorrhage in Eales’ disease. Methods: In the present retrospective study, medical records of patients who were treated with laser photocoagulation for vitreous hemorrhage due to Eales’ disease. The eyes were divided into 2 groups, the combined therapy group of laser photocoagulation and intravitreal bevacizumab, and the monotherapy group of laser photocoagulation. Best corrected visual acuity, vitreous hemorrhage grade were investigated at 1, 2, 6, and 9 months. Change of nonperfusion area and neovascularizaition area in fluorescein angiography were compared. Results: Among 14 eyes, 7 eyes underwent intravitreal bevacizumab injection and 7 eyes did not. Visual acuity improved significantly at 1 and 3 months in the combined therapy group, but not in the monotherapy group. Vitreous hemorrhage decreased significantly at 1 and 3 months in the combined group, and 1 month in the monotherapy group. There was significant difference in visual acuity at 3 months and in vitreous hemorrhage at 1 and 3 months between the groups. Neovascularizaiton area was significantly regressed only in combined therapy group (p=0.027). Conclusions: Combined laser photocoagulation with intravitreal bevacizumab injection decreased vitreous hemorrhage and neovascularization in Eales’ disease at 1 and 3 months after treatment. But these effect have not maintained thereafter.

목차

대상과 방법

결 과

고 찰

REFERENCES

키워드

Bevacizumab Eales disease Light coagulation